Deuterated Tetrazole CYP51 Inhibitor V23
2026-09-09
A 2025 European Journal of Medicinal Chemistry study describes V23, a deuterated tetrazole CYP51 inhibitor designed to improve fungal selectivity, metabolic stability, and activity against resistant pathogens. The compound showed broad in vitro activity, including against Aspergillus fumigatus, inhibited fungal phenotypic transitions and biofilms, displayed low mammalian-cell toxicity, and produced significant antifungal activity in vivo.
Oteseconazole (VT-1161) Candida Workflow
2026-09-09
Oteseconazole (VT-1161) enables concentration-controlled Candida susceptibility testing, resistant-isolate profiling, and mechanism-informed translational studies. Its fungal CYP51 selectivity supports focused antifungal experiments, while transporter findings caution researchers to separate target potency from broader drug-interaction risk.
JAK Inhibitors and Endothelial Cardiovascular Effects
2026-09-08
A comparative endothelial-cell study shows that JAK inhibitors can reduce inflammatory cytokine release without uniformly correcting adhesion, coagulation, or cell-survival abnormalities. The findings emphasize inhibitor-specific and concentration-dependent vascular effects that are important for interpreting cardiovascular risk in inflammatory disease research.
Multianimal MRI for Pancreatic Tumor Monitoring
2026-09-08
Kempinska et al. describe a four-chamber MRI workflow that images up to four KPC mice in one acquisition, improving the efficiency of tumor detection and longitudinal measurement. The protocol provides a practical framework for preclinical trial enrollment and for evaluating gemcitabine treatment response without replacing complementary pathological or molecular endpoints.
(-)-Norepinephrine (+)-bitartrate in Cardiovascular Models
2026-09-07
(-)-Norepinephrine (+)-bitartrate enables controlled adrenergic stimulation across vascular, renal, and cardiac assays. This practical guide connects receptor pharmacology with perfused-kidney workflows, cardiomyopathy research, and troubleshooting strategies that improve reproducibility.
FDA 2022 DDI Evidence: What Oteseconazole Adds
2026-09-05
This 2024 analysis integrates in vitro, clinical, and mechanistic data from FDA New Drug Application reviews to clarify enzyme- and transporter-mediated drug–drug interaction risk across 22 drugs approved in 2022. Its treatment of oteseconazole as a P-glycoprotein and/or BCRP inhibitor shows how regulatory DDI evidence can inform concomitant-medication assessment without being mistaken for direct evidence of antifungal efficacy.
Tacrolimus (FK506): Practical Research Workflows
2026-09-05
Build more reproducible calcineurin-inhibition experiments with Tacrolimus (FK506), from solvent handling and T-cell stimulation to cytokine and NFAT readouts. The workflow also shows how to distinguish FKBP12-dependent effects from cyclosporine-sensitive pathways and extend the compound into transplantation immunology research and tissue-model studies.
CUDC-907: Practical In Vitro Workflow
2026-09-04
CUDC-907 provides a single-reagent approach for investigating coordinated PI3K and HDAC pathway perturbation in cancer cell assays, including signaling, acetylation, cell-cycle, and apoptosis readouts. It is a research-use compound for validated laboratory workflows only and should not be used for diagnostic, therapeutic, or clinical applications.
Oteseconazole (VT-1161) Candida Assay Workflows
2026-09-04
Oteseconazole (VT-1161) combines potent fungal CYP51 inhibition with a practical profile for Candida isolate screening, resistance studies, and MIC-to-MFC confirmation. This guide translates reference-study methods into reproducible workflows while showing where the compound is informative—and where its activity should not be generalized.
AP1903 for Reliable FKBP Cell Assays
2026-09-03
Learn how AP1903 (SKU B4168) supports controlled FKBP fusion-protein activation, apoptosis pathway research, and conditional cell ablation. This scenario-based guide covers assay controls, dose interpretation, formulation, storage, and practical vendor-selection criteria.
Nipah Virus Polymerase Complex: Structural Insights
2026-09-03
The reference study defines the architecture of the Nipah virus L–P polymerase complex and separately resolves the connecting domain that helps organize catalytic functions. By combining cryo-electron microscopy, crystallography, and structural modeling, it identifies domain relationships and metal-ion features that clarify viral RNA synthesis and inform future polymerase-targeted antiviral research.
Predictive siRNA Codelivery with Netarsudil
2026-09-02
A 2026 Science Advances study developed a quantitative workflow for predicting which ionizable drugs can complex siRNA and support nanoparticle codelivery. Netarsudil was identified as a high-performing candidate and validated with CTGF-targeting siRNA in fibrotic human trabecular meshwork cells, linking formulation design with cytoskeletal and gene-regulatory outcomes.
Cepharanthine Workflows for Endometriosis Research
2026-09-02
Build a translational assay ladder for Cepharanthine, from stromal-cell viability and apoptosis assays to patient-derived endometrial organoids and murine lesion models. The workflow emphasizes solvent control, mechanism-resolved readouts, and troubleshooting strategies that distinguish selective biological activity from nonspecific toxicity.
AMG 487 CXCR3 Antagonist: Assay Workflows
2026-09-01
AMG 487 is a potent, selective CXCR3 antagonist for separating chemokine-driven migration, calcium signaling, and macrophage-state effects. This practical guide translates CXCL10-CXCR3 findings into reproducible workflows, with concentration planning, controls, troubleshooting, and limitations for inflammation and cancer biology research.
Affordable GRO-seq in Bread Wheat: Methods and Findings
2026-09-01
This protocol study improves Global Run-On sequencing (GRO-seq) for allohexaploid bread wheat by adding rRNA depletion after nuclear RNA isolation and before nascent RNA immunoprecipitation. The workflow increased the proportion of valid sequencing data by 20-fold in enhancer-transcription profiling, offering a practical strategy for reducing sequencing waste in large, complex genomes.
464 records 6/31 page Previous Next First page 上5页 678910 下5页 Last page